Organogenesis(ORGO)

Focus: Organogenesis is a public regenerative medicine and biologics company focused on wound care, orthopedic, and tissue regeneration therapies. With $433M in FY2025 revenue, they operate as a mid-cap biotech with a portfolio of FDA-approved and clinical-stage products.

Regenerative Medicine Biologics Wound Care Unknown

Profile data last refreshed 21h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

Should You Work at Organogenesis?

AI assessment

Organogenesis offers technical depth in regenerative medicine for specialists but carries execution risk due to revenue decline, minimal hiring, and below-average R&D investment despite recent pipeline catalysts.

Why Work Here

Public company status (NASDAQ: ORGO) with established $433M revenue base provides stability and equity upside potential versus private startups

Data completeness

5/9 — Partial

Company HealthStrong

Pipeline

Late-stage

8 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

5 open

Revenue

$433M

Key Products

Apligraf

Venous leg ulcers, epidermolysis bullosa, diabetic foot ulcers

Peak

Flagship product with Phase 3/4 programs across multiple chronic wound indications, demonstrating broad clinical utility and revenue generation.

Dermagraft

Diabetic foot ulcers, venous leg ulcers

Help build intelligence for Organogenesis

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Deep portfolio of 38 active clinical programs across regenerative medicine, wound care, and orthopedics offers diverse technical career paths and learning opportunities

Recent clinical wins (170-patient DFU study cleared key goal in April 2026) and upcoming regulatory catalysts (knee OA therapy moving toward FDA filing) signal momentum in pipeline progression

Watch Out For

Minimal hiring activity (only 4 open roles documented) suggests limited near-term growth or expansion plans, indicating constrained career advancement opportunities
Revenue declined 4% YoY ($451M in FY2024 to $433M in FY2025) with net income drop of 69% ($16M to $5M), signaling profitability pressures despite public status
Only 10% R&D intensity is below industry average for biotech, indicating lower investment in innovation relative to revenue and potentially limited resources for scientific advancement

Generated by Claude from Organogenesis's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Core commercial product with two Phase 3 programs underway, key to company's wound care market position.

Gintuit

Gingival recession, edentulous alveolar ridge

Growth

Periodontal regeneration asset with Phase 3 trial in gingival recession, targeting high-value dental market.

Pipeline & Clinical Trials

VCT-01

Wounds

N/A

Clinical Trials (1)

NCT01292122Safety Study of VCT-01™ in Split-Thickness Skin Graft Donor Site Wounds

N/A

Affinity

Venous Leg Ulcer

N/A

Clinical Trials (1)

NCT04901013Clinical Study Of Affinity Versus SOC In The Management Of VLUs

N/A

NuShield

Tendon Injuries

N/A

Clinical Trials (2)

NCT03828916NuShield in Surgical Peroneal Tendon Repair

N/A

NCT07510412Clinical Trial Evaluating NuShield® Plus Standard of Care (SOC) Versus Standard of Care (SOC) Alone in the Management of Non-Healing Venous Leg Ulcers (VLUs)

N/A

One or two level lumbar interbody fusion surgery

Degenerative Disc Disease

N/A

Clinical Trials (1)

NCT02808234Study of Nucel for One and Two Level Lumbar Interbody Fusion

N/A

Affinity Allograft

Diabetic Foot Ulcers

N/A

Clinical Trials (1)

NCT02880592Effect of Fresh Amniotic Membrane in the Treatment of Diabetic Foot Ulcers

N/A

PuraPly™ Antimicrobial Wound Matrix

Partial Thickness Wound

N/A

Clinical Trials (1)

NCT03286452The RESPOND Registry

N/A

NuCel with Autograft

Intervertebral Disc Disease

N/A

Clinical Trials (1)

NCT02023372Efficacy Study of NuCel® in Patients Undergoing Fusion of the Lumbar Spine

N/A

Gintuit

Gingival Recession

N/A

Clinical Trials (1)

NCT01547962A Pilot Clinical Trial of Gintuit (TM)in Establishing a Functional Zone of Attached Gingiva

N/A

PuraPly™ Antimicrobial Wound Matrix

Pressure Ulcer

N/A

Clinical Trials (1)

NCT03070938PuraPly™ Antimicrobial Wound Matrix and Wound Management

N/A

NuShield

Diabetic Foot Ulcer

N/A

Clinical Trials (1)

NCT03855514Randomized Clinical Study Assessing NuShield Versus Standard of Care in Diabetic Foot Ulcers

N/A

Standard of Care

Diabetic Foot Ulcer

N/A

Clinical Trials (1)

NCT06618612A Study to Evaluate the Efficacy of a Purified Native Type 1 Collagen Extracellular Matrix With Polyhexamethylene Biguanide Antimicrobial (PCMP) and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers

N/A

ReNu

Osteochondral Defect

N/A

Clinical Trials (1)

NCT03036878ReNu™ Marrow Stimulation Augmentation

N/A

PuraPly™ Antimicrobial Wound Matrix

Pressure Ulcers

N/A

Clinical Trials (1)

NCT03070925Prospective PuraPly™ AM Case Series Study